CD8A and cancer: Finally, treatment of tumor bearing mice with Early anti-PD-L1 and Late VSV-cDNA library in which the cDNA was sourced from a melanoma cell line (VSV-ASMEL) was also ineffective (Fig. 7F, orange line), showing that CD8+ T cell boosting against cancer type specific antigens is critical for these effects.